Zook In As Vivus CEO, But Turnaround Depends On Partnering
This article was originally published in The Pink Sheet Daily
Vivus has a new chairman and CEO after a proxy battle with a dissident shareholder ended in a settlement, but will the new management be able to find a marketing partner for Qsymia or broker an outright sale?
You may also be interested in...
The summary report of an interim analysis of the ongoing LIGHT clinical trial evaluating the cardiovascular safety of the obesity medicine can form the basis of a resubmission of the Contrave NDA, the company announced, shaving some time off the PDUFA clock.
Investors are closely following a Phase III study testing Wainua in ATTR cardiomyopathy, which could read out early in 2025.
It’s early days in the launch of Zurzuvae for postpartum depression, but Sage highlighted encouraging prescription trends during the company’s fourth quarter sales and earnings call.